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Abstract
Chemoprevention is a pragmatic approach to reduce the risk of colorectal cancer, one of the leading causes of cancer-
related death in western countries. In this regard, maslinic acid (MA), a pentacyclic triterpene extracted from wax-like
coatings of olives, is known to inhibit proliferation and induce apoptosis in colon cancer cell lines without affecting normal
intestinal cells. The present study evaluated the chemopreventive efficacy and associated mechanisms of maslinic acid
treatment on spontaneous intestinal tumorigenesis in ApcMin/+ mice. Twenty-two mice were randomized into 2 groups:
control group and MA group, fed with a maslinic acid–supplemented diet for six weeks. MA treatment reduced total
intestinal polyp formation by 45% (P,0.01). Putative molecular mechanisms associated with suppressing intestinal
polyposis in ApcMin/+ mice were investigated by comparing microarray expression profiles of MA-treated and control mice
and by analyzing the serum metabolic profile using NMR techniques. The different expression phenotype induced by MA
suggested that it exerts its chemopreventive action mainly by inhibiting cell-survival signaling and inflammation. These
changes eventually induce G1-phase cell cycle arrest and apoptosis. Moreover, the metabolic changes induced by MA
treatment were associated with a protective profile against intestinal tumorigenesis. These results show the efficacy and
underlying mechanisms of MA against intestinal tumor development in the ApcMin/+ mice model, suggesting its
chemopreventive potential against colorectal cancer.
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Introduction
Chemoprevention based on the use of bioactive plant
compounds has emerged as a practical approach to decrease the
risk of various cancers, including colorectal cancer, which is one of
the most frequent malignancies and one of the leading causes of
cancer-related death in western countries. Familial adenomatous
polyposis (FAP), a hereditary colorectal cancer predisposition
syndrome, is caused by a mutated adenomatous polyposis coli (Apc)
gene. FAP patients develop numerous colonic adenomas progress-
ing to colorectal cancer and small intestinal adenomas in most
cases. Interestingly, the ApcMin/+ mouse, a common animal model
of intestinal tumorigenesis, harbors a mutation in the same gene
that causes FAP and, like FAP patients, develops large numbers of
intestinal tumors at an early age [1]. Therefore, the ApcMin/+
mouse model is considered to be an analog of human intestinal
tumorigenesis and is extensively used to study chemotherapeutic
agents for humans.
Natural products have been exploited for treatment of human
diseases for thousands of years. Maslinic acid (MA), a natural
pentacyclic triterpene, is widely present in dietary plants, especially
in olive fruit skins. This compound has attracted much interest due
to its proven pharmacologic safety and its many biological
activities, such as anti-viral [2] and antidiabetogenic [3] functions.
More recently, some studies have shown that MA has anti-cancer
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capacity in different cell types, including melanoma [4], liver
cancer [5], astrocytoma [6] and colon cancer. Specifically in colon
malignancies, MA possesses potent differentiating and anti-
proliferation properties, inducing cell-cycle arrest in the G0/G1
phase and apoptosis in colon cancer cells without affecting non-
tumor cells [7]. However, because only a few, mainly in vitro,
studies have aimed to characterize the mechanisms of action of
olive components in colon cancer, further research is required.
Therefore, the main objective of the current study was to
determine the efficacy of MA consumption in preventing
spontaneous intestinal tumorigenesis in ApcMin/+ mice and to
characterize the mechanisms by which MA executes its function.
Materials and Methods
Animals and Treatment
A total of 22 male 4-week-old ApcMin/+ mice were purchased
from the Jackson Laboratories (Bar Harbor, ME) and maintained
in the animal facility at the University of Barcelona. Animal care
was strictly in accordance with the European Union Regulations.
The experimental protocols were approved by the Experimental
Animal Ethical Research Committee of the University of
Barcelona in accordance with current regulations for animal care
and use for experimental purposes. MA was obtained from olive
pomace by using the method described by Garcia-Granados et al.
[8]. The extract used was a white powder comprising 98%
maslinic acid and 2% oleanolic acid. This extract is stable when
stored at 4uC. After a 7-day acclimatization period receiving the
standard diet (Teklad Global 18% Protein rodent diet), animals
were randomly divided into two groups of 12 and 10 mice per
group (Control and MA, respectively). Control mice were fed with
the standard diet, and the MA-treated group was fed with the
same diet supplemented with 100 mg of MA/kg feed in order to
mimic the effective concentration inhibiting colon cancer cell
growth [7]. Diets were purchased from Harlan Interfauna Iberica
S.L (Barcelona, Spain). Animals were maintained for 12 h light/
dark cycles, with free access to water and food. Throughout the 6-
week treatment period, animals were observed for any signs of
toxicity; body weights and food and water intake were recorded
weekly. At the end of the 6 weeks, the animals were starved
overnight and anesthetized with volatile isoflurane (ESTEVE,
Barcelona, Spain) before blood samples were obtained by cardiac
puncture. Finally, mice were killed by an overdose of anesthesia.
Measurement of Intestinal Polyps
ApcMin/+ mice develop polyps in both the small and large
intestine, with a greater incidence of intestinal adenomas observed
in the former. Therefore, immediately after the mice were killed,
the small intestine was excised from each mouse, cut longitudi-
nally, and rinsed with phosphate-buffered saline solution (pH 7.4)
to remove intestinal contents. Intestines were pinned flat on
cardboard and then were fixed for 1 day in 4% neutral-buffered
formalin solution (v/v; pH 7.4). Intestinal sections were stored at
room temperature in 1% neutral buffered formalin solution (v/v)
until further analysis. To facilitate tumor quantification and
identification, the small intestine was divided into three equal-
length sections: proximal, medial, and distal. Thereafter, the small-
intestine sections were stained in phosphate-buffered saline
solution (pH 7.4) containing 0.1% (v/v) methylene blue. By using
a stereomicroscope and a measured grid, tumor number and
dimensions were determined for each small-intestine section. The
size of each intestine tumor was categorized as ,1 mm, 1–
1.9 mm, or $2 mm.
RNA Isolation and Gene Profiling by Affymetrix
Microarrays
The large intestine of each dead mouse was removed and placed
on a plastic plate, which was kept at 4uC. After removal of the
rectum, the colon was opened longitudinally with fine scissors, and
mucus and feces were washed away. The colonic mucosal layer
was incubated in Trizol (Invitrogen, Carlsbad, CA) for 3 min and
scraped off of the muscle layer with the edge of a sterile glass slide.
Cells were transferred into 800 mL Trizol, homogenized by
pipetting, and stored at 280uC until RNA extraction. RNA was
isolated by using a combination of two methods. First, total RNA
was isolated by using the Trizol method according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA). Subsequently,
it was purified by using the RNeasy Mini kit and digesting it with
DNase I (Qiagen, Germantown, MD) according to the manufac-
turer’s protocol. RNA pellets were resuspended in DEPC-treated,
RNase-free water, and their purity and quantity were determined
spectrophotometrically by using the NanoDrop ND-1000 (Nano-
Drop Technologies). RNA samples were considered suitable for
further processing if their absorbance ratio 260/280 was higher
than 1.9. Integrity was tested by using lab-on-a-chip technology on
the BioAnalyzer 2100 (Agilent, Palo Alto, CA, USA). Samples
were considered intact if they had an RNA integrity number (RIN)
above 8. Affymetrix microarrays on the Mouse Genome 430 2.0
platforms were performed according to the protocols published by
the manufacturer (Affymetrix). Five RNA samples chosen
randomly from the control and the MA group were analyzed.
Microarray Data Analyses
Data was standardized by using the Robust Multi-array
Average method [9] and quantile normalization. Differential gene
expression was assessed using the limma [10] package from
Bioconductor. Multiple testing adjustment of p-values was carried
out as described by Benjamini and Hochberg [11]. Biochemical
pathway analysis was conducted using Kyoto Encyclopedia of
Genes and Genomes (KEGG) Mapper, a collection of KEGG
mapping tools for KEGG pathway mapping. The Search&Color
Pathway tool was used to overlay gene expression results from
microarrays onto biochemical pathways found in KEGG. Gene
expression levels were denoted by color codes displayed on the
pathway by gene symbol boxes. Different shapes and pattern
boxes were used to represent induced and suppressed gene
expression. Enrichment analysis was based on MetaCore, an
integrated knowledge database and software suite for pathway
analysis of experimental data and gene lists. Enrichment analysis
consisted of matching gene IDs of possible targets for the
‘‘common’’, ‘‘similar’’, and ‘‘unique’’ sets with gene IDs in
functional ontologies in MetaCore. The probability of a random
intersection between a set of IDs and the size of target list with
ontology entities was estimated by the p-value of hypergeometric
intersection. A lower p-value indicates higher relevance of the
entity to the dataset, which shows in a higher rating for the entity.
The use of the False Discovery Rate (adjusted p-value) allowed
processes with doubtful significance in the experiment to be
rejected and ensures that findings are not contaminated with false
positives.
RT Real-Time PCR
The cDNA was synthesized in a total volume of 20 mL by
mixing 1 mg of total RNA, 125 ng of random hexamers
(Roche), 0.01 M dithiothreitol (Invitrogen), 20 units of RNAsin
(Promega), 0.5 mM dNTPs (Bioline), 200 units of M-MLV
reverse transcriptase (Invitrogen), and 4 mL 56 First-Strand
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Buffer (375 mM KCl, 15 mM MgCl2, 250 mM Tris-HCl,
pH 8.3) (Invitrogen). The reaction mixture was incubated at
37uC for 60 min. The cDNA product was used for subsequent
real-time PCR amplification. The mRNA levels of the selected
genes were determined in an ABI Prism 7000 Sequence
Detection System (Applied Biosystems) by using 9 mL of the
cDNA mixture and 11 mL of the specific primers in Master mix
(all from Applied Biosystems). b2 microglobulin (B2M) RNA
was used as an endogenous control. The reaction was
performed following the manufacturers recommendations.
Fold-changes in gene expression were calculated by using the
standard DDCt method. Experiments were carried out twice
using four samples each time for each condition.
Serum Sampling and NMR Metabolic Analysis
Blood samples were obtained by cardiopuncture of anesthetized
mice, and serum samples were obtained by centrifuging blood at
600 g at 4uC for 10 min. Macromolecules were removed from the
serum samples by using the ultrafiltration method described by
Gu¨nther et al. [12]. Briefly, NanoSep 3 K Omega centrifugal
devices were prepared by washing them 10 times with 0.5 mL
water +0.75 g/L sodium azide at 1100 g and 30uC for 1 h. Prior
to use, the mouse samples were stored at 280uC. When needed,
samples were thawed, filtered, and then spun at 9000 g at 4uC for
45 min. Then, 150 mL of the filtrate was diluted to obtain a 600-
mL NMR sample in buffer (60 mmol/L sodium phosphate,
10 mmol/L sodium azide, 0.5 mmol/L TMSP, 10% D2O,
pH 7.0). The samples were analyzed using a Bruker 500
spectrometer operating at 500.18 MHz with a 5 mm triple
resonance probe at 25uC. One-dimensional 1H NMR spectra
were obtained by using 128 transients, 16 steady-state scans, a
spectral width of 6009 Hz, 8192 pairs data points, and a 4.3 s
recycling time. Excitation sculpting was used for water suppres-
sion. The data were processed in NMRLab [13]. An exponential
line-broadening function of 0.3 Hz was applied, and the dataset
was zero-filled to 16384 data points prior to Fourier transforma-
tion. Spectra were phase-corrected manually and referenced to
TMSP (at 0 ppm). To compare peak volumes, the total area of
each spectrum, excluding the regions containing the residual water
signal and the TMSP signal, was normalized to 1. The peaks were
identified and quantified using the Chenomx NMR Suite with
associated libraries (version 4.5; Chenomx Inc., Edmonton,
Canada).
Results
MA Inhibits Intestinal Tumorigenesis in APCMin/+ Mice
During the experiment, all mice were monitored for body
weight and diet consumption. For the last three weeks, ApcMin/+
mice fed with MA showed significantly lower body weight gains
than did controls (Figure 1A). Moreover, MA-treated mice
showed a reduced food intake for the last two weeks (Figure 1B).
However, none of the animals fed with MA produced any sign
of distress or any gross changes in any organ, including liver,
lung, and kidney.
As shown in Figure 2A, MA prevented spontaneous intestinal
polyposis in ApcMin/+ mice. Dietary feeding with MA at 100 mg/
kg of feed significantly (P,0.01) suppressed intestinal polyp
formation by about 45% (9 tumors per mouse) when compared
with the control diet group (16 tumors per mouse). The most
important MA chemopreventive effect was observed on proximal
polyps (69%), followed by medial (4%) and distal polyps (28%)
(Figure 2B). In size distribution analysis of polyps, MA reduced the
occurrence or growth of ,1 mm diameter polyps by 44%, of 1–
2 mm diameter polyps by 33%, and of .2 mm diameter polyps
by 50% (Figure 2C).
Gene Expression Profile Induced by MA
To elucidate the underlying mechanisms by which MA inhibits
intestinal tumorigenesis in ApcMin/+ mice, we determined the
transcriptional profile of the ApcMin/+ mice’s colonic mucosa by
performing cDNA microarray analysis after MA feeding.
In the present study, we analyzed the expression profile of
45101 genes by performing whole mouse genome cDNA
microarrays. MA supplementation changed the expression of
2375 genes (p-value ,0.05), with an absolute fold-change of 1.5 or
more. Of these 2375 differentially expressed genes, 193 were
upregulated, and 2182 were downregulated (Table S1).
First, the list of differentially expressed genes between non-
treated and MA-treated mice was subjected to a KEGG molecular
pathway analysis using the KEGG Mapper tool to identify possible
enrichment of genes with specific biological activities. Figure 3
depicts the KEGG colorectal cancer pathway using KEGG
Mapper and shows that MA downregulated glycogen synthase
kinase 3b (Gsk3b), a protein involved in Wnt/b-catenin signaling
that is affected in ApcMin/+ mice. Interestingly, MA also inhibited
Cyclin D (Ccnd1) (Figure 3), a gene expressed after the
transcriptional activation of b-catenin.
Moreover, MA treatment downregulated the expression of the
Akt1 gene, which codes for the protein AKT (protein kinase B,
PKB) (Figure 3), a serine/threonine kinase critical in controlling
cell survival, insulin signaling, angiogenesis, and tumor formation;
the Tpr53 gene (Figure 3), encoding protein p53, which regulates
cell cycle, apoptosis, senescence, metabolism, and DNA repair; the
Msh6 gene (Figure 3), involved in the post-replicative DNA
mismatch repair system (MMR) and the Tgfb1 gene and its
receptor (Tgfb1r1) (Figure 3).
On the other hand, MA caused upregulation of deleted in
colorectal carcinoma (Dcc) gene (Figure 3), encoding the pro-
apoptotic protein DCC. However, MA also downregulated
DIP13a (Appl1), a mediator of the DCC apoptotic pathway
(Figure 3). Furthermore, MA reduced the expression of the anti-
apoptotic protein Bcl-2 (Figure 3).
Pathway analysis performed using KEGG Mapper was com-
plemented with an independent analysis by MetaCore to obtain a
p-value for each pathway. According to the GeneGO Maps Folder
in Metacore, the maps containing genes corresponding to
cytoskeleton remodeling, transcription, cell cycle, cell adhesion,
immune response, apoptosis, and survival in normal and
pathologic TGF-b-mediated regulation of cell proliferation were
the most significantly modulated (Table 1). In addition to the
aforementioned cell-cycle-associated genes, Metacore analysis
identified downregulation of Cdk4, Cdk6, Btrc, Junb, and Ppp2r4
(Table 1, cell cycle). On the other hand, apart from the apoptosis-
related genes already mentioned, Metacore analysis revealed the
downregulation of the anti-apoptotic gene Bcl2l1 (Bcl-XL) (Table 1,
apoptosis and survival). Moreover, diverse genes involved in signal
transduction pathways that avoid apoptosis have been shown to be
modulated in MA-treated mice. Concretely, MA downregulated
Shc1, Grb2, Sos1, Rps6ka2, Ywhae, Ywhag, Prkar2b, and Prkaca gene
expression.
Validation of Microarray Data by RT-PCR
The changes in mRNA expression observed in the micro-
arrays for Ccnd1, Cdk4, Bcl2, Shc1, Cd44 and Sorbs1 were
validated by performing RT real-time PCR assays (Figure 4).
These targets were selected for RT real-time PCR analysis on
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PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e59392
the basis of their significant participation in the chemopreven-
tive effects produced in ApcMin/+ mice by MA supplementation.
Metabolic Profile of Blood Serum Induced by MA
1H NMR spectroscopy detected a wide range of metabolites in
ApcMin/+ mice blood serum. Upon analyzing the spectra, several
metabolites were seen to vary between MA-treated and control
groups. Whereas glucose and 3-hydroxybutyrate were clearly
different between the two groups, some metabolites, such as
acetoacetate, acetate, acetone, lactate, valine, alanine, leucine,
lysine and creatine, followed an imperfect trend with sample
dependent variations (Table 2). Quantification and comparison of
1H NMR results for well-resolved peaks showed that MA
supplementation gave 3-hydroxybutyrate levels of 125612% in
the MA group compared to the control group whereas it reduced
the levels of glucose to 8969% of that of the control group
(Table 2). Moreover, other metabolites, including citrate, pyru-
vate, glutamine, phenylalanine, tyrosine, isoleucine, urea and
allantoin, were clearly identified but did not show differences
between the MA and control groups (Table 2).
Discussion
MA supplementation inhibits spontaneous intestinal polyposis
without producing any sign of distress or toxicity in APC Min/+
mice. MA-treated mice showed a loss of weight (Figure 1A) that, at
least partly, could be attributed to the reduced food intake
(Figure 1B). In turn, the decrease in food intake might be related to
a satiety effect or differences in energy metabolism produced by
MA [14].
MA treatment significantly reduced total intestinal polyp
formation in ApcMin/+ mice (Figure 2A). However, this effect
was statistically nonsignificant, probably due to fewer polyps and
high variability, when polyps were classified by size or zone, except
for polyps in the proximal small intestine (Figure 2B & C). MA
showed differential efficacy suppressing intestinal polyp formation
depending on small-intestine segment (Figure 2B). This is in
agreement with previous evidence that some dietary and
pharmaceutical compounds provide cancer protection only in
parts of the small intestine [15]. These effects could be related to
several physiologic conditions through the gastrointestinal tract,
such as pH, expression pattern of several enzymes, microbiota,
and concentration due to intestinal content. All these conditions
can modify the chemical structure of a chemopreventive agent and
Figure 1. Body weight and diet consumption monitoring. A) Effects of MA treatment on body weight. B) Effects of MA feeding in food intake.
Data represented as mean 6 SEM (* *, p,0.01).
doi:10.1371/journal.pone.0059392.g001
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Figure 2. MA feeding inhibits intestinal polyposis in APCMin/+ mice. A) Total number of polyps/mouse in the small intestine of ApcMin/+ mice.
B) Number of polyps/mouse in proximal, medial and distal sections. C) Number of polyps/mouse shown by polyp size distribution (,1 mm diameter
polyps, 1–2 mm and .2 mm). Data represented as mean 6 SEM (* *, p,0.01).
doi:10.1371/journal.pone.0059392.g002
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influence its final metabolism and, consequently, its anticancer
effect. For example, resveratrol is almost completely conjugated
upon oral administration, and the most bioactive metabolites are
its glucuronide and sulfate derivatives [16,17]. The inhibitory
efficacy depending on polyp size was more homogeneous,
suggesting that MA inhibits both the appearance and development
of intestinal polyps (Figure 2C).
Comparison of microarray expression profiles of MA-treated
and control mice revealed that MA downregulates the expression
of the Gsk3b (GSK3b) gene (Figure 3). As mentioned above,
ApcMin/+ mice contain a mutation in APC that, together with
Axin and GSK3b, operates by activating b-catenin degradation in
Wnt/b-catenin signaling pathway. Therefore, the mutation of the
Apc gene present in the ApcMin/+ mouse produces a cytosolic
accumulation and an increase in nuclear translocation of b-
catenin. In the nucleus, b-catenin interacts with the transcription
factor T cell factor/lymphoid enhancer factor (TCF/LEF), leading
to an increase in the expression of survival genes, including c-Myc,
Cyclin D1, and Cyclooxygenase-2 (Cox-2) [18]. However, GSK3b has
also been linked to a prosurvival signal in a Wnt/b-catenin-
independent manner. In this regard, GSK3b is constitutively
activated in colon cancer cells, where it is implicated in
tumorigenesis and cancer progression. Accordingly, the downreg-
ulation of GSK3b inhibits proliferation and enhances apoptotic
cell death in chronic lymphocytic leukemia B cells, renal cancer
cells, pancreatic cancer cells, and colon cancer cells [19,20]. These
results may indicate that MA confers a protective effect by
inhibiting GSK3b.
Overexpression of Akt is an early event in colorectal carcino-
genesis [21], thus the lower expression of Akt in MA-treated mice
may be related to the inhibition of intestinal polyp growth in
ApcMin/+ mice. Another common clinicopathologic feature of
colorectal carcinoma is the presence of mutations in p53 (Tpr53).
Regarding APCMin/+ mice, p53 inactivation has been reported to
have little effect on the incidence or the progression and apoptosis
of adenomas [22]. Nevertheless, inhibition of p53 in mice treated
with MA indicates that the death process is p53-independent.
Furthermore, advanced colorectal adenomas usually present
changes in transforming growth factor beta (TGFb) signaling.
Generally, cancerous cells increase their production of TGFb,
which acts on the secreting cancerous cells themselves and on
surrounding cells regulating cell growth, differentiation, and
apoptosis [23]. Thus, reduction of TGFb signaling induced by
MA through the downregulation of Tgfb1 and Tgfb1r1 may be
involved in the inhibition of tumorigenesis in ApcMin/+ mice. Also
in the advanced stages of colorectal pathogenesis, deleted in
Figure 3. Adaptation of KEGG colorectal cancer pathway using KEGG Mapper. Circular pathway members were significantly up-regulated
and rectangular members were found to be down-regulated in the intestinal mucosa of ApcMin/+ mice treated with MA. Horizontal lines indicate a
fold change (FC) of between 1.5 and 2 and vertical lines a FC of more than 2.
doi:10.1371/journal.pone.0059392.g003
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colorectal carcinoma (Dcc) gene expression appears to be lost or
markedly reduced. This gene encodes a netrin 1 receptor that
functions as a tumor suppressor via its ability to trigger tumor cell
apoptosis [24]. MA caused upregulation of DCC, indicating a pro-
apoptotic effect. However, a mediator of the DCC apoptotic
effect, DIP13a (Appl1), was downregulated by MA treatment.
DIP13a interacts with a region on the DCC cytoplasmic domain
that is required for the induction of apoptosis [25]. However,
DIP13a also binds many other proteins, including RAB5A,
AKT2, PI3KCA, and adiponectin receptors to regulate cell
proliferation and adiponectin and insulin signaling. Given that
little is known about DIP13a, its inhibition by MA could indicate a
beginning of MA-resistance in ApcMin/+ mice, antagonizing DCC
apoptotic activation but also modulating other DIP13a biological
functions.
Moreover, expression analysis revealed that the induction of
apoptosis by MA is based on the downregulation of the anti-
apoptotic genes Bcl-2 and Bcl2l1 (Bcl-XL) (Table 1, apoptosis and
survival). Therefore, this downregulation by MA acts as a pro-
apoptotic stimulus. This finding is in agreement with that of a
recent study where western blotting analysis showed that the
treatment of the HT29 human colon adenocarcinoma cell line
with MA induced the repression of Bcl2 [26]. Besides, different
signal transduction pathways that save cells from apoptosis were
inhibited by MA. For instance, MA downregulated epidermal
growth factor receptor (EGFR) signaling, which is related to
mitogenesis and tumorigenesis. After EGFR activation, a trimeric
complex between tyrosine phosphorylated Shc, Grb2, and Sos is
formed and this, in turn, triggers downstream mitogenic signaling
[27]. MA exerted this action by downregulating Shc1, Grb2, and
Sos1 gene expression. Furthermore, MA treatment reduced the
expression of the Rps6ka2 gene, coding for the protein p90Rsk, a
downstream mediator of the mitogen-activated protein kinase
(MAPK) pathway, which has been reported to inhibit apoptosis via
the stimulation of binding of Bad to 14-3-3 and the inactivation of
Bad-mediated cell death [28]. Interestingly, MA also triggered this
apoptotic action by inhibiting the expression of Ywhae and Ywhag,
which code for different members of the family of 14-3-3 proteins,
and thus reducing Bad sequestration and increasing Bad-induced
apoptosis via the mitochondrial death pathway [29]. In addition,
MA reduced the expression of Prkar2b and Prkaca coding for the
regulatory subunit type II-beta of the cAMP-dependent protein
kinase (PKA RII-beta) and the catalytic subunit alpha of the
cAMP-dependent protein kinase (PKA C-alpha), respectively.
PKA is a serine/threonine kinase that is activated by cyclic
adenosine monophosphate (cAMP). Effects of PKA on apoptosis
are likely to be largely dependent on the cell type and the
mechanisms by which apoptosis is induced [30]. In the case of
ApcMin/+ mice, treatment with a PKA antagonist, Rp-8-Br-
cAMPS, reduces tumor promotion and b-catenin levels, nuclear
Table 1. Pathways modified in the colon mucosa of ApcMin/+ mice by MA treatment as found in Metacore.
GeneGO Maps/Modulated pathways $p-value {Significant/total genesModulated genes
Cytoskeleton remodeling
TGF, WNT and cytoskeletal remodeling (Q) 3,57E209 23/111 Ncl, Tgfb1, Tgfbr1, Wnt5a, Fzd7, Dvl1, Dock1, Akt1, Gsk3b,
Map3k7, Mapk14, Limk2, Ppard, Trp53, Ccnd1, Cfl1, Actn1,
Arpc4, Sos1,Grb2, Pxn, Tln1, Shc1
Cytoskeleton remodeling (Q) 4,91E207 16/102 Ncl, Tgfb1, Tgfbr1, Dock1, Gsk3b, Map3k7, Mapk14, Limk2,
Cfl1, Actn1, Arpc4, Sos1,Grb2, Pxn, Tln1, Shc1
Transcription
CREB pathway (Q) 1,18E207 16/44 Akt1, Mapk14, Ccnd1, Sos1, Grb2, Shc1, Clca2, Camk2g,
Gprc5a, Prkcb, Prkar2b, Rps6ka2, Cdo1, Prkaca, Fbxw5,
Fbxw11
Cell cycle
Regulation of G1/S transition (part 1) (Q) 1,61E207 11/38 Cdk4, Cdk6, Junb, Btrc, Ppp2r4, Anapc1, Tgfb1, Tgfbr1,
Gsk3b, Ccnd1, Ccnd2
Cell adhesio´n
Chemokines and adhesion (Q) 3,55E207 19/100 Dock1, Akt1, Gsk3b, Limk2, Cfl1, Actn1, Arpc4, Sos1,Grb2,
Pxn, Tln1, Shc1, Thbs1, Cd44, Cd47, Itga3, Msn, Flot2, Eif4g1
Immune response
Signaling pathway mediated by IL-6 and IL-1 (Q) 3,56E206 9/27 Sos1,Grb2, Shc1, Il6st, Jak1, Ikbkap, Nfkbie, Irak1, Cebpb
IL-15 signaling (Q) 2,19E206 12/64 Akt1, Mapk14, Sos1,Grb2, Shc1, Il2rg, Adam17, Nfkbie, Prkce,
Ets1, Bcl2, Bcl2l1
MIF - the neuroendocrine-macrophage connector (q) 1,92E204 3/46 Plcb2, Pla2g4c, Itpr2
PIP3 signaling in B lymphocytes (q) 1,34E204 5/42 Plcb2, Pik3r1, Itpr2, Foxo3, Igh-6
Apoptosis and survival
BAD phosphorylation (Q) 4,21E206 11/42 Bcl2, Bcl2l1, Sos1, Grb2, Shc2, Rps6ka2, Ywhae, Ywhag,
Ppm1g, Prkar2b, Prkaca
Normal and pathological TGF-beta-mediated regulation of cell proliferation
Normal and pathological TGF-beta-mediated
regulation of cell proliferation (Q)
2,71E206 10/33 Tgfb1, Tgfbr1, Gsk3b, Mapk14, Trp53, Ccnd1,Sos1,Grb2, Shc1,
Map2k6
More significantly modulated pathways in Metacore using genes with FC.1.5 and adjusted p-value,0.01.q/Q, activation/inhibition of the biological process by MA;
$p-value that corresponds to the GeneGO Map/Pathway.
{Ratio between the number of significantly modulated genes by MA and the total number of genes per GenenGO Map/Pathway in Metacore.
doi:10.1371/journal.pone.0059392.t001
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translocation, and expression of some of its target genes, such as c-
Myc and cyclooxygenase-2 (Cox-2) [31].
On the other hand, MA inhibited the expression of some genes
related to cell cycle (Table 1, cell cycle). Cell cycle progression is
highly controlled by a complex network of signaling pathways that
eventually converge to regulate the activity of cyclin/cyclin-
dependent kinase (CDK) complexes. There are different members
of the CDK family, and each CDK is dependent on a particular
cyclin partner [32]. In this regard, MA downregulated the gene
expression of Cyclin D (Ccnd1), which drives the G1 phase
progression. In agreement with this result, the results of other
studies have related MA antitumor activity to an inhibition of
Cyclin D1 expression [33]. Moreover, MA reduced the expression
of Cyclin D partners during G1 phase, Cdk4 and Cdk6, inhibiting
the G1 cyclin-CDK complexes and leading to G1-phase cell-cycle
arrest. Specific and timely proteolysis of cell-cycle regulators by the
ubiquitin-proteasome system represents an important mechanism
that ensures proper progression through the cell cycle in a
unidirectional and irreversible manner. Furthermore, in cancer
cells, deregulation or suppression of the proteasome is supposed to
induce uncontrolled proteolysis and is linked to having a more
sensitive profile to drugs than that of normal cells [34]. MA
inhibited the ubiquitin ligase SKP1–CUL1–F-box-protein (SCF)
complex by downregulating the Btrc gene. bTrCP protein
pertaining to the F-box family is the substrate-recognition
component of the SCF ubiquitin ligase complex, which mediates
the ubiquitination and subsequent proteasomal degradation of
target proteins involved in cell-cycle checkpoints, protein transla-
tion, cell growth, and survival. Interestingly, bTrCP plays an
important role allowing G1/S transition and also mediates the
degradation of the pro-apoptotic protein BimEL to promote cell
survival [35] and has been reported to be overexpressed in
colorectal tumors [36]. Hence, its downregulation by MA could be
related to cell cycle arrest and subsequent inhibition of spontane-
ous polyposis in ApcMin/+. Additionally, MA modulates other cell-
cycle regulatory proteins. For example, MA suppresses the
expression of the gene encoding the oncogenic protein JunB,
which is an essential component of the activating protein-1 (AP-1)
transcription factor that is involved in the control of cell growth,
differentiation, inflammation, and neoplastic transformation. It is
noteworthy that a recent study demonstrated that the chemopre-
ventive effects of MA in Raji cells depends on the inhibition of
nuclear factor-kB (NF-kB) and the activation of Activator protein
(AP-1) [37]. Another protein controlling cell growth and division
that was downregulated in ApcMin/+ mice after treatment with MA
was a regulatory subunit of protein phosphatase 2A (PP2A)
(Ppp2r4). This protein has been described to dephosphorylate b-
catenin, acting as a positive regulator of Wnt signaling [38,39].
Moreover, Ppp2r4 function is essential for cell survival [38,39].
Therefore, MA’s downregulation of the gene encoding this protein
could be involved in its antitumor effect.
Additionally, evidence is accumulating to suggest that proteins
involved in regulating actin cytoskeleton and cell adhesion also
participate in mitogenesis, either as unique transducers of growth
signals or as monitors of anti-apoptotic conditions, or both [40,41].
In this regard, MA downregulated several genes related to
cytoskeleton remodeling and cell adhesion such as Cd44 (Table 1,
cytoskeleton remodeling and cell adhesion). A recent study using
short hairpin RNA against CD44 to silence its expression in
SW620 colon cancer cells showed that reduced expression of the
protein inhibited cell proliferation, migration, and invasion. In
agreement with our results, reduced expression of CD44 induced
Figure 4. Validation of genes that were differentially expressed in the colon mucosa of ApcMin/+ mice after MA treatment by RT-
PCR. Mean 6 SD are shown. *, p,0.05; * *, **p,0.01, versus the untreated condition. n = 8/group.
doi:10.1371/journal.pone.0059392.g004
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the same effects that we describe for MA, cell cycle arrest in the
G1 phase and apoptosis via the downregulation of Bcl-2 and Bcl-
xL, and also via the upregulation of BAX [42].
Regarding DNA repair system, MA inhibited the expression of
the Msh6 gene (Figure 3). DNA repair is associated with the
prevention of mutagenesis and cancer but can also be associated
with the detection and repair of mismatches derived from
chemically induced DNA damage with genotoxic agents. In this
regard, the utility of genotoxic drugs is often limited by the
enhanced ability of cancer cells to repair their DNA. Therefore,
attenuation of the DNA repair system sensitizes tumor cells to
DNA-damaging agents [43]. Notably, MA has been reported to
interfere with DNA integrity in HT29 cells [26]; hence, it could be
acting, at least in part, as a genotoxic agent. In this case, Msh6
downregulation could trigger DNA damage and posterior
apoptosis. Anyway, inhibition of only one DNA repair system
would hardly affect final repairing activity due to the functional
redundancy of MMR proteins.
Finally, MA also downregulated immune system–related genes
(Table 1, immune response). Inflammation and immune system
responses have controversial effects in cancer, either by preventing
and inhibiting tumor development or, when inflammation
becomes chronic, by promoting the growth and progression of
cancer [44]. In this regard, chronic inflammation plays a decisive
role in the development and sustenance of intestinal adenomatous
polyps in the ApcMin/+ mice [45]. Accordingly, MA has been
implicated in anti-inflammatory and immune-attenuating actions
via suppression of NFkB [46]. Therefore, in this case, the
downregulation of immune system responses by MA may reduce
tumor growth. Regarding also immune function, it is noteworthy
that MA inhibits the expression of Cxcr4 gene (Table S1), encoding
for chemokine (C-X-C motif) receptor 4, which allows HIV
infection [47]. Hence, this result may explain the anti-HIV activity
of MA [48].
On the other hand, 1H NMR spectroscopy results can be
explained by some of the genetic modulations induced by MA.
The decrease in serum glucose concentration in ApcMin/+ mice
treated with MA could be a consequence of the upregulation of the
c-Cbl–associated protein (CAP) encoded by Sorbs1. CAP plays a
critical role in insulin-regulated GLUT4 translocation [49] and
hence, its activation by MA promotes glucose cellular uptake.
Moreover, low glucose levels in mice serum can be due to a
glycogen accumulation triggered by MA treatment. First, glycogen
reservoirs are regulated by the aforementioned GSK3b. This
protein, apart from its role in Wnt and pro-survival signaling, is
able to phosphorylate and inhibit glycogen synthase activity,
impairing glycogen synthesis. Thus, inhibiting GSK3b by MA
implies an activation of glycogen accumulation. Second, MA also
reduced Phka1 expression. Because the Phka1 gene encodes PHK
protein, which activates glycogen phosphorylase and leads to the
conversion of glycogen into glucose-1-phosphate, by downregu-
lating PHK MA inhibits glycogen degradation. In addition to
these transcriptional modifications, MA has been described as a
potent direct inhibitor of glycogen phosphorylase, thus triggering
glycogen reservoir accumulation [50]. A significantly increase in
the ketone body 3-hydroxybutyrate level was also found in serum
Table 2. List of metabolites identified for 1H NMR data by Chenomx database in ApcMin/+ mice serum.
Serum samples from maslinic acid-treated mice were:
Perfect trends AUC Control AUC MA {% MA/Control $p-value
Q Glucose 3.930e+0961.531e+08 3.504e+0962.353e+08 8969 0,0229




















q/Q Higher/Lower in MA-fed group when compared with the control diet group.
{Ratio between the area under the curve (AUC) in MA and the AUC in controls for the corresponding metabolite.
$p-value relative to difference between MA and control.
doi:10.1371/journal.pone.0059392.t002
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from MA-treated mice. The decrease in serum glucose may
contribute to the increase in serum ketone body concentrations
because, although ketone body synthesis occurs normally under all
conditions, its formation increases as glucose availability drops. To
support the elevated ketone body synthesis in MA-treated mice,
high fatty acid oxidation is necessary for the production of acetyl-
CoA used as substrate. In mice treated with MA, fatty acid
degradation is activated by the upregulation of Cpt1, which
encodes carnitine palmitoyltransferase I (CPT I), the mitochon-
drial gateway for fatty acid entry into the matrix and, thus, the
main controller of fatty acid oxidation. It is noteworthy that this
observation may be involved in the loss of weight detected in
ApcMin/+ mice after MA treatment. Moreover, our results are in
agreement with previous studies describing antihyperlipidemic
[51] and antihyperglycemic [14] activities for MA. Given that
accumulating evidence suggests that obesity [52] and hyperglyce-
mia [53] are associated with increased risk of colorectal cancer, the
metabolic changes induced by MA treatment are potentiating its
chemoprotective effect in ApcMin/+ mice.
Taken together, our data show that MA is a nontoxic agent that
effectively inhibits intestinal polyposis in genetically predisposed
ApcMin/+ mice. The cancer chemopreventive effects of MA are
mainly related to the modulation of cancer progression–related
genes, suggesting an induction of a G1-phase cell-cycle arrest and
activation of apoptosis by a p53-independent mechanism.
Moreover, the expression of genes related to energy metabolism
is altered by MA to support a protective metabolic profile. In
summary, our findings provide the first in vivo evidence that MA is
a promising nutraceutical for colon cancer prevention.
Supporting Information
Table S1 Differentially expressed genes by MA treat-
ment in the colon mucosa of APCMin/+ mice. List of
differentially expressed genes assessed using the limma package
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